In an article titled “Novel female sexual dysfunction drug effective, phase III studies show”, published June 19, 2017, the name of the company marketing Addyi and one of Dr. Clayton’s disclosures was misstated. The name of the company is Valeant.

Ads

You May Also Like

PORT boosts survival in N2 NSCLC patients

FROM THE JOURNAL OF CLINICAL ONCOLOGY Modern postoperative radiotherapy, or PORT, appears to provide ...

Switch to oral fingolimod produces better MS outcomes

For patients who have active multiple sclerosis despite using injectable immunomodulators, switching to the ...

Antisclerostin osteoporosis drugs might worsen or unmask rheumatoid arthritis

FROM SCIENCE TRANSLATIONAL MEDICINE Antisclerostin monoclonal antibodies have shown their ability to increase bone ...